If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Launch Optimization
Download FREE Excerpt
9 Info Graphics
15 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
The last decade has seen Medical Affairs move from a support function to a strategic, central function in biopharma. Change has been constant with Medical becoming the hub for insight and intelligence for the company, taking the lead in shaping the evidence agenda, establishing excellence in external engagement and value communication. Additionally, the Covid-19 pandemic has triggered a tsunami of rapid digital technological adoptions for Medical Affairs.
This research explores Medical’s role in product launch. The research probes medical activity timelines, and performance metrics. It further explores critical success factors and digital implementation for launch preparedness.
The study engaged 60 executives from 43 leading life sciences companies. Medical Directors and VPs represent nearly four-fifths of the leaders who shared data and insights on Medical launch activities in this study
Pharmaceutical; Medical Device; Biotech; Biopharmaceutical; Diagnostic; Health Care; Chemical; Consulting; Consumer Products; Clinical Research; Laboratories; Science
Adamas Pharmaceuticals; AstraZeneca; Alcon; Albireo; Apellis Pharmaceuticals; ASC Therapeutics; Baxter Healthcare; BELLUS Health; Boehringer Ingelheim; BIAL; bioMerieux; Cardinal Health; Cipla; Eisai; EMD Serono; Genentech; Fidia; Eurofarma; GlaxoSmithKline ; GW Pharmaceuticals; Ipsen; Helsinn; Karyopharm Therapeutics; Kyowa Kirin; Labaid Group; Matinas BioPharma; Lundbeck; MEDiSTRAVA; Melinta Therapeutics; Inc; Merck Serono; NextGen Healthcare; Novartis; Pfizer; Pixacore; Gedeon Richter ; Sandoz; Sanofi; Santen; Sunovion; Takeda Pharmaceuticals; Thermo Fisher; Terumo Corporation; Vertex Pharmaceuticals
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.